| Literature DB >> 29176971 |
Mariasofia Caltagirone1, Elisabetta Nucleo1, Melissa Spalla1, Francesca Zara1, Federica Novazzi1, Vittoria M Marchetti1, Aurora Piazza1,2, Ibrahim Bitar1,3, Marica De Cicco1, Stefania Paolucci4, Giorgio Pilla5, Roberta Migliavacca1, Laura Pagani1.
Abstract
To evaluate the water compartment antibiotic-resistance contamination rates, 11 wells, five streams, and four treatment plants located in the Oltrepò Pavese area were screened for the presence of third generation cephalosporins resistant Gram-negative bacteria. Enterobacteriaceae were also characterized for the Extended-Spectrum-β-Lactamases (ESBLs), carbapenemases, and mcr-1 genes presence. From December 2014 to November 2015, 246 water samples were filtered, plated on Plate Count Agar, MacConkey Agar, and MacConkey Agar with cefotaxime. Isolates were species identified using AutoSCAN-4-System and ESBLs, carbapenemases, and colistin resistance determinants were characterized by PCR, sequencing, and microarray. Plasmid conjugative transfer experiments, PCR-based Replicon typing, Pulsed-Field Gel Electrophoresis, Multi-Locus-Sequence-Typing, and in-silico plasmid characterization were performed. A total of 132 enterobacteria isolates grew on MacConkey agar with cefotaxime: 82 (62.1%) were obtained from streams, 41 (31.1%) from treatment plants, and 9 (6.8%) from wells. Thirty out of 132 (22.7%) isolates, mainly belonging to Escherichia coli (n = 15) species, showed a synergic effect with piperacillin-tazobactam. A single ESBL gene of blaCTX-M-type was identified in 19/30 isolates. In further two E. coli strains, a blaCTX-M-1 gene co-existed with a blaSHV-type ESBL determinant. A blaSHV-12 gene was detected in two isolates of E. coli (n = 1) and Klebsiella oxytoca (n = 1), while any ESBL determinant was ascertained in seven Yersinia enterocolitica strains. A blaDHA-type gene was detected in a cefoxitin resistant Y. enterocolitica from a stream. Interestingly, two Klebsiella pneumoniae strains of ST307 and ST258, collected from a well and a wastewater treatment plant, resulted KPC-2, and KPC-3 producers, respectively. Moreover, we report the first detection of mcr-1.2 ST10 E. coli on a conjugative IncX4 plasmid (33.303 bp in size) from a stream of Oltrepò Pavese (Northern Italy). Both ESBLs E. coli and ESBLs/carbapenemase-producing K. pneumoniae strains showed clonal heterogeneity by Pulsed-Field Gel Electrophoresis and Multi-Locus-Sequence-Typing. During one-year study and taking in account the whole Gram-negative bacterial population, an average percentage of cefotaxime resistance of 69, 32, and 10.3% has been obtained for the wastewater treatment plants, streams, and wells, respectively. These results, of concern for public health, highlight the need to improve hygienic measures to reduce the load of discharged bacteria with emerging resistance mechanisms.Entities:
Keywords: Gram-negative bacteria; carbapenemases; colistin resistance; molecular characterization; water ecosystems
Year: 2017 PMID: 29176971 PMCID: PMC5687051 DOI: 10.3389/fmicb.2017.02232
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1Map of the Oltrepò Pavese Plain showing the sampling sites. P, Well; T, Stream; TP, Wastewater Treatment Plant.
Oligonucleotides used for PCR and sequencing.
| FW 5′-ATGTGCAGYACCAGTAARGT-3′ | 50 | 593 | |
| REV 5′-TGGGTRAARTARGTSACCAGA-3′ | |||
| FW 5′-GGTTAAAAAATCACTGCGTC−3′ | 50 | 1,000 | |
| REV 5′- TTGGTGACGATTTTAGCCGC-3′ | |||
| FW 5′- ATGGTGACAAAGAGAGAGTGCA-3′ | 56 | 835 | |
| REV 5′- CCCTTCGGCGATGATTCTC-3′ | |||
| FW 5′-GCCCGGGTTATTCTTATTTGTCGC-3′ | 60 | 900 | |
| REV 5′-TCTTTCCGATGCCGCCGCCAGTCA-3′ | |||
| FW 5′-ATGAGTATTCAACATTTCCG-3′ | 59 | 800 | |
| REV 5′-CTGACAGTTACCAATGCTTA-3′ | |||
| FW 5′-TGTCACTGTATCGCCGTC-3′ | 55 | 1,000 | |
| REV 5′-CTCAGTGCTCTACAGAAAACC-3′ | |||
| FW 5′-CAGATTGCCGATGGTGTTTGG-3′ | 55 | 523 | |
| REV 5′-AGGTGGGCC ATTCAGCCAGA-3′ | |||
| FW 5′-GGAATAGAGTGGCTTAATTCTC-3′ | 50 | 361 | |
| REW 5′-GTGATGCGTCYCCAAYTTCACT-3′ | |||
| FW 5′-GGTTTGGCGATCTGGTTTTC-3′ | 52 | 621 | |
| REW 5′-CGGAATGGCTCATCACGATC-3′ | |||
| FW: 5′-TTGGTGGCATCGATTATCGG-3′ | 52 | 743 | |
| REV: 5′-GAGCACTTCTTTTGTG ATGGC-3′ | |||
| FW: 5′-CGGTCAGTCCGTTTGTTC-3′ | 46 | 309 | |
| REV: 5′-CTTGGTCGGTCTGTAGGG-3′ |
Ta, annealing temperature;
primers used only in the PCR reaction.
Bacterial counts and percentage of 3GCs resistance for each sampling site.
| 1T | 11 | 4, 625 ± 1, 552 | 41 | 0–100 |
| 2T | 11 | 4, 627.3 ± 1, 551 | 46 | 0–100 |
| 3T | 11 | 3, 694.9 ± 1, 507 | 5.3 | 0–40 |
| 4T | 11 | 5, 764.3 ± 1, 997 | 68 | 0–100 |
| 5T | 11 | 7, 317.3 ± 1, 385 | 49.5 | 0–100 |
| 6T | 9 | 4, 500 ± 1, 739 | 42.7 | 0–100 |
| 7T | 11 | 8, 272.7 ± 1, 159 | 46 | 0–100 |
| 8T | 10 | 1, 023.3 ± 997.4 | 3.75 | 0–32.4 |
| 9T | 11 | 3, 709.1 ± 1, 504 | 25.3 | 0–100 |
| 10T | 11 | 3, 696.8 ± 1, 507 | 6.4 | 0–40 |
| 11T | 11 | 2, 812.7 ± 1, 392 | 18.8 | 0–90 |
| 1P | 12 | 16.4 ± 6.8 | 20 | 0–100 |
| 2P | 10 | 2, 033.5 ± 1, 328 | 12.9 | 0–100 |
| 3P | 10 | 1, 039.5 ± 995 | 10 | 0–0.2 |
| 4P | 10 | 36 ± 15 | 10.3 | 0–77 |
| 5P | 10 | 12.9 ± 5.3 | 10 | 0–100 |
| 6P | 10 | 8, 020 ± 1, 320 | 7 | 0–25 |
| 9P | 10 | 9, 005 ± 995 | 13 | 0–50 |
| 10P | 11 | 6, 050 ± 1, 612 | 6.6 | 0–25 |
| 11P | 10 | 17.5 ± 10 | 5 | 0–50 |
| 12P | 11 | 1, 003 ± 999 | 0 | 0 |
| 13P | 10 | 1, 028.2 ± 864 | 18 | 0–100 |
| TP Varzi | 6 | 10,000 | 50.8 | 25–100 |
| TP Broni | 3 | 10,000 | 100 | 100 |
| TP Voghera | 3 | 5, 100 ± 4, 000 | 75 | 25–100 |
| TP Stradella | 3 | 6, 733.3 ± 3266 | 52 | 25–100 |
% CTX-R, % Cefotaxime-resistance; SE, standard error.
P, Well; T, Stream; TP, Wastewater Treatment Plant;
Refers to the number of visits to each site;
% CTX-R, percentage of 3GCs- resistant Gram-negatives obtained as an average value, in dependence from the overall visits performed at the same sampling site.
% CTX-R range, percentage 3GCs-resistant Gram-negatives, obtained comparing the bacterial growth on MCA and MCA+CTX, range 0–100%, depending on the single visit and sampling site.
Mean values of total bacterial count and percentage of 3GCs-resistance (±SE) from stream samples during different seasons.
| Bacterial Count (CFU/ml) | 5, 196.485 ± 862 | 6, 687.636 ± 815.45 | 3, 137.4 ± 1, 005 | 2, 231.179 ± 766.8 |
| % CTX-Resistance | 36.3 ± 6.9 | 46.3 ± 7.8 | 12.8 ± 2.95 | 15.5 ± 6.2 |
Molecular characteristics of ESBLs/AmpC/carbapenemases-producing isolates recovered from streams, wells, and WWTPs.
| 993 | 6P | June 2015 | 6P | AMC, AMP, CTX, ERT | CTX-M-1 | IncP (P) , IncL (L), IncF (FIA) |
| NTe | 7T | March 2015 | 7T | AMC, AMP, CAZ, PIP, CTX | CTX-M-14 | IncF (FIA), IncU (U) |
| 131 | 1T | January 2015 | 1T | AMP, CAZ, CTX, FEP, CIP, PIP, LEV, MOXI, NOR, TOB, TMS | CTX-M-1 | IncF (FIB), Inc FII (FII) |
| 94 | 3T | January 2015 | 3T | AMC, AMP, CAZ, CTX, FEP, PIP, ERT, MEM, TZP, CIP, CL, MOXI, NOR | CTX-M-28, TEM-1 | IncP (P), IncF (FIB) |
| 6151 | 11T | May 2015 | 11T | AMC, AMP, CAZ, CTX, FEP, PIP, TZP | SHV-12 | IncN (N), Inc B/O (B/O), IncF (FIB) |
| 5717 | 1TP | June 2015 | TP Broni | AMC, AMP, CTX, CAZ, FEP, PIP, CIP, LEV, MOXI, NOR, TOB, CL, FOS | CTX-M-28 | IncHI2 (HI2), Inc B/O (B/O), IncF (FIA, FIB), IncA/C (A/C), IncFII (FII) |
| 5590 | 2TP | July 2015 | TP Broni | AMP, FEP, CTX, CAZ, PIP, CIP, CL, MOXI, NOR, LEV, | CTX-M-14 | IncX1 (X1) |
| 7519 | 3TP | October 2015 | TP Broni | AMP, FEP, CTX, CAZ, PIPCIP, CO, MOXI, NOR, LEV, TMS, TOB | CTX-M-138 | IncHI2 (HI2), IncM (M) |
| 5080 | 1TP | June 2015 | TP Stradella | AMP, CTX, FEP CIP, CO, GM, MOXI, NOR, LEV, TMS, TOB | CTX-M-1 | IncF (FIA, FIB) |
| 3132 | 1TP | May 2015 | TP Varzi | AMP, CTX, FEP, PIP, TMS | CTX-M-15 | IncF (FIA), IncT (T) |
| 399 | 2TP | May 2015 | TP Varzi | AMP, CTX, CIP, LEV, MOXI, NOR, PI, TMS | CTX-M-15 | IncF (FIA) |
| 7228 | 3TP | May 2015 | TP Varzi | AMP, CTX, CAZ, FEP, PIP | CTX-M-138 | IncN (N), IncF (FIA, FIB) |
| 2432 | 4TP | June 2015 | TP Varzi | AMP, CTX, FEP, PIP CIP, MOXI, NOR, LEV | CTX-M-1 | IncM (M), IncN (N), HIBM (NA)d, FIBM (NA)d |
| 2208 | 5TP | June 2015 | TP Varzi | CIP, MOXI, NOR, LEV | CTX-M-14 | IncL (L), IncF (FIA, FIB) |
| 362 | 6TP | July 2015 | TP Varzi | AMP, CTX, CAZ, PIP, CIP, MOXI, NOR, LEV, GM, TMS | CTX-M-1, SHV-5 | IncP (P), IncF (FIA, FIB) |
| 10 | 7T | November 2015 | 7T | AMC, AMP, CAZ, PIP, TMS, CO | CTX-M-1, SHV-12, MCR-1.2 | IncX4 (X4), IncX3 (X3) |
| NTe | 6T | April 2015 | 6T | AMC, AMP, CAZ, PIP, CTX | SHV-12 | IncHI2 (HI2), IncN (N), Inc F (FIA) |
| NTe | 9T | December 2014 | 9T | PIP, AMP, CTX, FEP, FOS | CTX-M-1 | IncN (N), R (NA)d |
| 258 | 9P | June 2015 | 9P | AMC, AMP, CAZ, CTX, PIP, CO | KPC-3 | IncFII K (FIIk, FIB KQ) |
| 456 | 2T | January 2015 | 2T | AMC, AMP, CAZ, CTX, FEP, PIP, CL, GM | CTX-M-1 | IncN (N) |
| 1266 | 1TP | May 2015 | TP Varzi | AMP, CTX, FEP, PIP | CTX-M-15 | IncF (FIA), IncT (T) |
| 1601 | 2TP | May 2015 | TP Varzi | AMC, AMP, CAZ, FEP, PIP, CL | CTX-M-28 | IncHI1 (HI1), Inc B/O (B/O), IncF (FIA) |
| 194 | 3TP | May 2015 | TP Varzi | AMP, CAZ, CTX, FEP, PIP, TMS | CTX-M-15, TEM-1 | IncM (M), IncN (N), IncB/O (B/O), IncF (FIIK) |
| 1601 | 4TP | May 2015 | TP Varzi | AMP, CTX, CAZ, FEP, PIP, CL, CIP, MOXI, NOR, LEV | CTX-M-15 | IncHI1 (HI1), IncL (L) |
| 307 | 5TP | July 2015 | TP Varzi | AMC, AMP, CTX, CAZ, FEP, MEM, ERT, TZP, CIP, NOR, MOXI, FOS, GM, TMS, CL | TEM-1, KPC-2 | IncFIIK (FIIk, FIB KN, FIB KQ) |
| NTe | 1T | June 2015 | 1T | AMC, AMP, CTX, FOS | Other mechanism | NTe |
| NTe | 2T | March 2015 | 2T | AMC, AMP, CTX, PIP | Other mechanism | NTe |
| NTe | 3T | May 2015 | 3T | AMC, AMP, CTX, PIP | Other mechanism | NTe |
| NTe | 6T | January 2015 | 6T | AMC, AMP, CTX, CAZ, CL | Other mechanism | NTe |
| NTe | 6T | February 2015 | 6T | AMC, AMP, CTX, CAZ | Other mechanism | NTe |
| NTe | 6T | March 2015 | 6T | AMC, AMP, CTX, CAZ | Other mechanism | NTe |
| NTe | 11T | May 2015 | 11T | AMC, AMP, CTX, PIP | Other mechanism | NTe |
| NTe | 11T | June 2015 | 11T | AMC, AMP, CTX, PIP | DHA-type | NTe |
P, well; T, stream; TP, Treatment Plant;
AMC, amoxicillin/clavulanic acid; AMP, ampicillin; CAZ, ceftazidime; CIP, ciprofloxacin; CL, chloramphenicol; CO, colistin; CTX, cefotaxime; ERT, ertapenem; FEP, cefepime; FOS, fosfomycin; GM, gentamicin; LEV, levofloxacin; MEM, meropenem; MOXI, moxifloxacin; NOR, norfloxacin; PIP, piperacillin; TZP, piperacillin-tazobactam, TOB, tobramycin; TMS, trimetoprim/sulfametoxazol.
Inc, incompatibility group;
.
Phenotipical and molecular characteristics of 3GCs-resistant transconjugants; comparison with E. coli and Klebsiella spp. donors resistance and β-lactamases.
| 1T | IncF (FIB) | ||
| 3T | AMC, | IncP (P), IncF(FIB) | |
| 7T | AMC, AMP, CAZ, PIP, TMS, | CTX-M-1, | IncX4 (X4) |
| 11T | IncF (FIB) | ||
| 1TP | AMC, | IncHI2 (HI2), IncF (FIA, FIB) | |
| 2TP | IncX1(X1) | ||
| 1TP | IncT (T) | ||
| 2TP | IncF (FIA) | ||
| 3TP | IncF (FIA, FIB) | ||
| 6TP | IncF (FIA, FIB) | ||
| 1TP | IncF (FIA, FIB) | ||
| 1TP | IncF (FIA) | ||
| 3TP | IncN (N) | ||
| 5TP | IncFIIk (FIIk, FIBKQ) | ||
| 9T | IncN (N), R (NA |
AMC, amoxicillin/clavulanic acid; AMP, ampicillin; CAZ, ceftazidime; CIP, ciprofloxacin; CL, chloramphenicol; CO, colistin; CTX, cefotaxime; ERT, ertapenem; FEP, cefepime; FOS, fosfomycin; GM, gentamicin; LEV, levofloxacin; MEM, meropenem; MOXI, moxifloxacin; NOR, norfloxacin; PIP, piperacillin; TZP, piperacillin-tazobactam; TOB, tobramycin; TMS, trimetoprim/sulfametoxazol;
Inc, incompatibility group,
NA, not assigned.
The antibiotic resistance and the determinants transferred in the transconjugants are underlined and provided in bold.
Figure 2(A) Cluster analysis of the ESBL-producing E. coli isolates. (B) Comparison between the profiles of 1T E.coli and 20LOM E. coli. Date of isolation (month, year), resistance determinants and ST are also included. The scale bar at the top (left) indicates similarity coefficient (%).
Figure 3Cluster analysis of the seven ESBLs- or carbapenemases- producing K. pneumoniae. Date of isolation (month, year) and resistance determinants are also included. The scale bar at the top (left) indicates similarity coefficient (%).
Figure 4Linear map of the pIBMC_MCR1.2 plasmid, showing the genetic structures surrounding mcr-1.2 gene.